H.C. Wainwright Reiterates Buy Rating on Werewolf Therapeutics Inc. (HOWL)

H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating and $15.00 price target on Werewolf Therapeutics Inc. (NASDAQ: HOWL).

The analyst commented: "If an improved therapeutic window, an emerging monotherapy profile and the possibility of improving safety sounds familiar—it is because it exemplifies what Werewolf reported during ASCO’24 for WTX-124 (IL-2) and may now also be the case for WTX-330 (IL-12 INDUKINE). While we note the data is early with small patient numbers (n=11), we believe the PREDATOR platform continues to deliver on its promise of both improving the therapeutic window for cytokine therapies, opening a path to an improved tolerability profile. We reiterate our Buy and our price target of $15."

For an analyst ratings summary and ratings history on Werewolf Therapeutics Inc. click here. For more ratings news on Werewolf Therapeutics Inc. click here.

Shares of Werewolf Therapeutics Inc. closed at $2.34 yesterday.

You May Also Be Interested In